Korean Clinical Practice Guidelines: Current Status of Adherence to the RIGHT Checklist

Miyoung Choi 1*, You Kyung Lee 2*, Soo Young Kim 3 and on behalf of the Executive Committee for CPGs, The Korean Academy of Medical Sciences

1Division of Health Technology Assessment Research, National Evidence-based Healthcare Collaborating Agency, Seoul, Korea
2Department of Laboratory Medicine and Genetics, Soochunhyang University College of Medicine, Bucheon, Korea
3Department of Family Medicine, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea

ABSTRACT

Background: The Korean Academy of Medical Sciences (KAMS) has been utilizing AGREE II to audit the quality of clinical practice guidelines (CPGs) developed in Korea. Monitoring the RIGHT Checklist adherence could help monitor the quality status and discover areas for improvement of CPG development.

Methods: We included 129 CPGs from the past 5 years and assessed each item of the RIGHT Checklist. STATA version 15.0 was used for statistical analysis.

Results: Among the seven sections of the RIGHT checklist, sections with a full compliance rate over 60% were 'basic information' (65%) and 'background' (66%). The other sections' mean full compliance rates were 'Evidence' 52%, 'Recommendation' 35%, 'Review and quality assurance' 25% and 'Funding, declaration and management of interest' 17%. Sections with a partial compliance rate over 60% were 'Recommendation' (60%) and 'Funding, declaration and management of interest' (70%). Non-compliance was highest in the 'Review and quality assurance' (17%) domain. In comparison between groups 1 (under median group) and 2 (over median group), group 2 showed a tendency to have multi-stakeholder involvement and present sufficient information on financial resources and conflict of interest declarations. For the CPGs developmental methodology aspect, group 2 provided more pertinent information than group 1 about supporting evidence-making and the process from evidence to recommendation.

Conclusion: This study evaluated adherence to the RIGHT Checklist of CPGs developed in Korea. It can provide helpful information to develop strategic plans for enhancing the capabilities of developing CPGs in Korea.

Keywords: Practice Guidelines; Evidence-based Medicine; Current Status; RIGHT Checklist; AGREE II; Reporting Guide

INTRODUCTION

The first CPG recorded in the Korean Medical Guideline Information Center (KoMGI), which is operated by the Korean Academy of Medical Sciences (KAMS), was the Korean Guideline for Asthma in 1994.1 However, the development of clinical practice guidelines (CPGs) in...
Disclosure
The authors have no potential conflicts of interest to disclose.

Author Contributions
Conceptualization: Lee YK. Data curation: Choi M. Formal analysis: Choi M. Investigation: Kim SY, Choi M. Methodology: Lee YK, Kim SY. Software: Choi M. Validation: Choi M, Lee YK, Kim SY. Writing - original draft: Lee YK, Choi M. Writing - review & editing: Kim SY.

Western countries started in the 1980s, increased rapidly in the 1990s, and the number of publications related to CPGs exceeded 1,000 per year in the 2000s. As such, Korea has had less history and experiences related to CPG development than Western countries.

To overcome these weaknesses and quickly enhance the ability for development of CPGs by academic societies under the KAMS, the KAMS has formed the committee for guidelines development & management in 2008 and the committee was renamed the Executive Committee for CPGs (ECC). The ECC comprises multidisciplinary experts, including EBM methodology, medicine, nursing, public health, etc., and aims to improve the overall quality of CPG development related to clinical healthcare in Korea. ECC has provided irregular educational programs for CPG developers and disseminates information about the methodology used to develop CPGs to achieve the committee’s purpose. From 2017, ECC launched multiple formal training courses for Korean CPG developers, and the reporting checklists for CPGs were included in the curriculum since 2018.

ECC developed the AGREE II scoring guide in 2012 and began education programs for AGREE II and its scoring guide from 2013. Besides, the ECC launched the KAMS Appraisal System for CPGs in 2013, and some of the medicine or EBM experts who receive AGREE II education each year are appointed as a KAMS certified appraiser after a series of follow-up training courses. The ECC has consistently sought to increase inter-rater reliability and to construct a consensus on the requirements required in each AGREE II item. The activities of the KAMS Appraisal System for CPGs was reflected in the development process of the CPG developers. As a result, the quality of the CPGs developed in Korea has been improved to some extent. KAMS utilizes AGREE II as an essential means of auditing the quality status of the domestically developed CPGs, reflecting the results observed in a year-long assessment in its KAMS training program for the following year (Fig. 1). With the growing interest in the development of CPGs and the quantitative expansion of published CPGs in Korea, the direction of ECC’s efforts was not limited to the AGREE II instrument and has also gradually changed in the direction of strengthening the methodologies.
As reporting standards for CPGs, there are currently two checklists in the EQUATOR (Enhancing the QUAlity and Transparency Of health Research) Network for newly developed CPGs: the AGREE (Appraisal of Guidelines, REsearch and Evaluation) Reporting Checklist and the Reporting Items for Practice Guidelines in Healthcare (RIGHT) Checklist. The AGREE Reporting Checklist was announced by the AGREE research team and each item on the checklist originated and reformatted from the AGREE II and intended to improve the comprehensiveness, completeness, and transparency of reporting in practice guidelines. The RIGHT Checklist developed by the RIGHT development group, which consisted of a multidisciplinary international team that included policymakers, methodologists, epidemiologists, clinicians, editors, and consumer representatives, had a purpose of assisting guideline developers when reporting their guidelines, supporting journal editors and peer reviewers when considering guideline reports, and helping healthcare practitioners understand and implement a guideline.

The AGREE II has been utilized to audit the quality status of domestically developed CPGs. The requirements of the RIGHT and the AGREE Reporting Checklists have a lot in common, but they differ in some aspects. For example, the RIGHT Checklist requires specifying CPG in the title but not in the AGREE Reporting Checklist. Moreover, only the RIGHT Checklist requires descriptions related to the epidemiologic background regarding the health problem, how outcomes were selected and sorted regarding the healthcare questions, and the quality assurance process. Additionally, subgroup consideration of target population and developer’s information should be provided more evidently in the RIGHT than the AGREE. With the reasons mentioned above, the ECC agreed that the RIGHT Checklist might be more transparent and explicit in some critical aspects for CPG developers. Monitoring the RIGHT Checklist adherence could be a useful means to monitor the quality status and discover areas of improvement of CPGs. This study aims to find less compliant areas to the RIGHT Checklist of guidelines developed in Korea from January 2014 to April 2019. ECC believes that assessing the current compliance status with the RIGHT Checklist can give feedback to the ECC’s strategic plan and improve existing deficiencies.

**METHODS**

**Inclusion of guidelines**

The authors published an article entitled ‘Current Status of Clinical Practice Guidelines in Korea’ in the February issue of this journal. We have analysed the level of adherence with the RIGHT checklist for all 129 CPGs included in the last issue. To briefly describe the inclusion process, we collected Korean CPGs in the past five years (from 2014 to April 2019) through several electronic database searches (MEDLINE, EMBASE, and KoreaMed), hand searches, and surveys of academic society memberships from the KAMS. Three authors selected CPGs according to our inclusion/exclusion criteria. The inclusion criteria were as follows: 1) conforms to CPG definitions and 2) developed within the last five years (since January 2014). The exclusion criteria were as follows: 1) does not include recommendations, 2) nonmedical fields (dental, nursing, alternative medicine, etc.), 3) CPGs not for Koreans, and 4) if updated, the previous version.

**Scoring compliance to the RIGHT Checklist**

Three authors (MC, YKL, and SYK) independently assessed CPGs according to each item of the RIGHT Checklist. The RIGHT Checklist consists of 22 topics grouped in 7 sections: basic information, background, evidence, recommendations, review and quality assurance,
funding, declaration and management of interest, and other information. Ten topics in the RIGHT Checklist have more than one item. For example, topic 1 (title/subtitle) was divided into 3 items (1a. identify the report as a guideline, 1b. describe the year of publication, 1c. describe the focus of the guideline) that were scored independently. Adherence levels were divided into three levels, which are full, partial or non-compliance, and scored 2, 1, or 0, respectively. Full compliance was defined if the relevant content is sufficiently described anywhere on the CPG, not considering which section should be attributed. Partial compliance was defined if some of the relevant content was described. Non-compliance was defined if the relevant content cannot be found. We did not consider weight difference by items because of the definition and importance of each item for development guideline process. Two assessors were assigned for each CPG and scored the technical precision of the RIGHT Checklist items based on the adherence levels of: 0 (non-compliance), 1 (partial-compliance), and 2 (full-compliance). They then went through the consensus process. If any CPG had been in full compliance for all 35 items, this CPG could score a total of 70 points.

Data analysis
The score was summarized and compliance rate of each items was calculated. The summarized score of guidelines did not showed normal distribution, therefore the median value was calculated. Based on the median value 49, we divided guidelines into two group. Group 1 was classified as under median value and Group 2 was classified as over median value. We compared the compliance rate of RIGHT Checklist between two groups by sections and each item.

Pearson χ² test was used for comparison of groups, and STATA version 15.0 was used for statistical analysis.

RESULTS

Adherence to the RIGHT Checklist
The total score of each guideline was summarized and the median value was 49 (interquartile range: 43- 54). And the mean average scores by topics of RIGHT Checklist were calculated (Fig. 2). Among the seven topics of the RIGHT Checklist, topics with a full compliance rate over 60% were ‘basic information’ (65%), and ‘background’ (66%). The other topics’ mean full compliance rates were ‘Evidence’ 52%, ‘Recommendation’ 35%, ‘Review and quality assurance’ 25% and ‘Funding, declaration and management of interest’ 17%.

Topics with a partial compliance rate over 60% were ‘Recommendation’ (60%), and ‘Funding, declaration and management of interest’ (70%). Non-compliance was highest in the ‘Review and quality assurance’ (17%) domain. Each topic’s detailed items and results are summarized in Table 1

Comparison between the two groups
Based on the median value of the summarized score, guidelines were classified as Group 1 (n = 62), which had a lower acquisition than median value 49, and Group 2 (n = 67), which had a higher score of the median value. Table 2 and Table 3 show a comparison of the characteristics of guidelines and methodology description.

Table 2 shows the difference in the development process between groups in terms of transparency in development. Firstly, regarding the multidisciplinary grouping of the
guideline development group (GDG), we divided groups by the number of institutions or academic specialties that participated. Groups with over three institutions or specialties were considered as a multidisciplinary group. Group 2 showed a higher proportion of multidisciplinary than Group 1 (65.7% vs. 32.3%, group difference: $P < 0.001$). Ninety percent of guidelines in Group 2 mentioned the funding source. However, 70% of group 1 mentioned the funding sources, and 29.0% did not mention them. Disclosure of conflicts of interest were reported more in Group 2 guidelines than Group 1 (79.1% vs. 53.2%, group difference: $P = 0.002$).

Table 3 shows differences in methodology description between groups. Evidence level description rate was higher in Group 2 guidelines than Group 1 (98.5% vs. 61.3%, group difference: $P < 0.001$). Methodology for recommendation grading was well reported in Group 2 (97.0%), but in Group 1, the reported rate was 59.7%, and the not reported rate was 40.3%. Reporting the consensus process was also higher in Group 2 (89.6%); however, in Group 1, the reported rate was 62.9%, and not mentioned guidelines were 23 (37.1%).

In terms of CPGs developmental structure and process between groups 1 and 2, there were significant differences in the number of specialty groups involved, information for the funding source, declaration, and management of interest. Group 2 has shown a tendency to have multi-stakeholder involvement and present sufficient information on financial resources and conflict of interest declarations. For the CPGs developmental methodology aspect, group 2 provided more sufficient information compared to group 1 about the supporting evidence-making and the process from evidence to the recommendation.

**DISCUSSION**

To summarize the current status with RIGHT Checklist compliance of CPGs developed in Korea, topics in ‘basic information,’ ‘background,’ and ‘evidence’ showed full compliance in over 50% of CPGs. In contrast, topics in ‘review and quality assurance,’ ‘funding, declaration and management of interest,’ and ‘other information’ showed full compliance in 25%, 17%,

![Fig. 2. Mean average score of RIGHT Checklist compliance by section.](https://jkms.org)
and 18% of CPGs, respectively. This is thought to result from the relatively short history and less experience with CPG development, although guideline developers are well-trained in writing scientific research papers. Nevertheless, the RIGHT Checklist’s topic ‘funding, declaration and management of interest’ have been continuously emphasized in KAMS.

Table 1. Summary of right checklist compliance rate (Total N = 129)

| Variables                                      | 2 (Full compliance) | 1 (Partial-compliance) | 0 (Non-compliance) | Not applicable |
|------------------------------------------------|----------------------|-------------------------|--------------------|----------------|
| **Basic information**                          |                      |                         |                    |                |
| Title/subtitle                                 | 125 (97)             | 4 (3)                   | 0 (0)              | 0 (0)          |
| 1b (year)                                      | 49 (38)              | 3 (2)                   | 77 (60)            | 0 (0)          |
| 1c (focus)                                     | 98 (76)              | 27 (21)                 | 4 (3)              | 0 (0)          |
| Executive summary                              | 19 (15)              | 103 (80)                | 7 (5)              | 0 (0)          |
| Abbreviation/acronyms                          | 83 (64)              | 46 (36)                 | 0 (0)              | 0 (0)          |
| Corresponding developer                        | 126 (98)             | 1 (2)                   | 0 (0)              | 0 (0)          |
| Section average                                | 83.3 (65)            | 31 (24)                 | 14.7 (11)          | 0 (0)          |
| **Background**                                 |                      |                         |                    |                |
| Brief description of health problem            | 116 (90)             | 13 (10)                 | 0 (0)              | 0 (0)          |
| Aims of guideline and specific objectives      | 112 (87)             | 17 (13)                 | 0 (0)              | 0 (0)          |
| Target population                              | 106 (82)             | 23 (18)                 | 0 (0)              | 0 (0)          |
| 7b (subgroup)                                  | 102 (79)             | 25 (19)                 | 2 (0)              | 0 (0)          |
| End-users and setting                          | 92 (71)              | 36 (28)                 | 1 (1)              | 0 (0)          |
| Guideline development group                    | 72 (56)              | 54 (42)                 | 3 (2)              | 0 (0)          |
| Section average                                | 85.4 (66)            | 42.1 (33)               | 1.5 (1)            | 0 (0)          |
| **Evidence**                                   |                      |                         |                    |                |
| Healthcare questions                           | 89 (69)              | 37 (29)                 | 3 (2)              | 0 (0)          |
| Systematic review                              | 59 (46)              | 67 (52)                 | 3 (2)              | 0 (0)          |
| Guideline development group                    | 69 (53)              | 54 (42)                 | 6 (5)              | 0 (0)          |
| Assessment of the certainty of the body of     | 80 (62)              | 31 (24)                 | 18 (14)            | 0 (0)          |
| evidence                                       | Section average       | 66.6 (52)               | 45 (35)            | 6.4 (5)        | 11 (9) |
| Recommendations                                 | 94 (73)              | 35 (27)                 | 0 (0)              | 0 (0)          |
| Rational/explanation                           | 76 (59)              | 52 (40)                 | 1 (1)              | 0 (0)          |
| Evidence to decision process                   | 80 (62)              | 31 (24)                 | 18 (14)            | 0 (0)          |
| Section average                                | 45.1 (35)            | 78 (60)                 | 5.9 (5)            | 0 (0)          |
| **Review and quality assurance**               |                      |                         |                    |                |
| External review                                | 41 (32)              | 67 (52)                 | 21 (16)            | 0 (0)          |
| Quality assurance                              | 23 (18)              | 83 (64)                 | 23 (18)            | 0 (0)          |
| Section average                                | 32 (25)              | 75 (58)                 | 22 (17)            | 0 (0)          |
| **Funding, declaration and management of interest** |                      |                         |                    |                |
| Funding source and roles of the funder         | 31 (24)              | 89 (69)                 | 9 (7)              | 0 (0)          |
| Declaration and management of interest         | 18a (source)         | 30 (23)                 | 82 (64)            | 17 (13)        |
| Declaration and management of interest         | 18b (roles of funder)| 18 (14)                 | 93 (72)            | 18 (14)        |
| Section average                                | 22 (17)              | 90.3 (70)               | 16.75 (13)         | 0 (0)          |
| **Other information**                          |                      |                         |                    |                |
| Access                                         | 30 (23)              | 82 (64)                 | 17 (13)            | 0 (0)          |
| Suggestions for further research               | 14 (11)              | 114 (88)                | 1 (1)              | 0 (0)          |
| Limitations of the guideline                   | 25 (19)              | 97 (75)                 | 7 (5)              | 0 (0)          |
| Section average                                | 23 (18)              | 97.7 (76)               | 8.3 (6)            | 0 (0)          |

Values are presented as number (%). QA = quality assurance, COI = conflict of interest.
Appraisal System for CPGs. The corresponding assessment items of the AGREE II instrument are items 22 and 23, “The views of the funding body have not influenced the content of the guideline,” and “Competing interests of GDG members have been recorded and addressed,” respectively. However, the RIGHT Checklist guides CPG developers that they provide 1) funding source (18a) and 2) roles of funders (18b) for item 22, and 3) the types of conflict of interests (COI) (19a) and 4) how developers managed their COIs (19b) for item 23. As mentioned earlier, KAMS has continuously tried to educate and train on the AGREE II since 2013.

Generally, in the assessment tool, related items presented a declarative sentence compared to the checklist. However, with the RIGHT Checklist, those comprehensive sentences are divided into four specific check items. So, CPG developers can remain aligned with the AGREE II item for related descriptions using the RIGHT Checklist. We believe this finding supports that the KAMS Appraisal System should consider introducing a self-check system using the RIGHT Checklist before submitting the CPG.

The RIGHT Checklist has been included in ECC’s education program from 2018. However, based on the current analysis, education for the RIGHT Checklist needs to be strengthened through diversified delivery methods, such as an interactive, hands-on workshops in addition to existing knowledge transfer methods. Even though 69% of CPGs have scored full compliance on item 10a, the authors all agreed that closed assistance from a methodology expert was necessary during the relevant CPG developmental stage. This decision reflected the experiences in consulting the individual GDG who converted clinical questions to PICO

---

**Table 2. Difference in development process between groups**

| Description                        | Group 1 (Partial) (Total n = 62) | Group 2 (Well) (Total n = 67) | Pearson $\chi^2$ test ($P$) |
|------------------------------------|----------------------------------|-------------------------------|-----------------------------|
| Multidisciplinary in GDG (9a)      |                                  |                               |                             |
| Multidisciplinary (≥ 3)            | 20 (32.3)                        | 44 (65.7)                     | 14.382                      |
| Single or two (1 or 2)             | 42 (67.7)                        | 23 (34.3)                     | (*** $P < 0.001$)           |
| Funding Source (18a)               |                                  |                               |                             |
| Reported                           | 44 (71.0)                        | 61 (91.0)                     | 8.571                       |
| Not reported                        | 18 (29.0)                        | 6 (9.0)                       | (*** $P < 0.003$)           |
| Declare of COI (19a)               |                                  |                               |                             |
| Yes                                | 33 (53.2)                        | 53 (79.1)                     | 9.70                        |
| No                                 | 29 (46.8)                        | 14 (20.9)                     | (*** $P < 0.002$)           |

Values are presented as number (%).
Group 1 (partial compliance group): Guidelines converted RIGHT scores were under median level 49, Group 2 (well compliance group): Guidelines converted RIGHT scores were over median level 49.

GDG = guideline development group, COI = conflict of interest.

* $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$.

**Table 3. Difference in methodology description between groups**

| Description                        | Group 1 (Partial) (Total n = 62) | Group 2 (Well) (Total n = 67) | Pearson $\chi^2$ test ($P$) |
|------------------------------------|----------------------------------|-------------------------------|-----------------------------|
| Evidence level (12)                |                                  |                               |                             |
| Yes                                | 38 (61.3)                        | 66 (98.5)                     | 28.55                       |
| No                                 | 24 (38.7)                        | 1 (1.5)                       | (*** $P < 0.001$)           |
| Recommendation grading (13c)       |                                  |                               |                             |
| Yes                                | 37 (59.7)                        | 65 (97.0)                     | 27.13                       |
| No                                 | 25 (40.3)                        | 2 (3.0)                       | (*** $P < 0.003$)           |
| Consensus process (15)             |                                  |                               |                             |
| Reported                           | 39 (62.9)                        | 60 (89.6)                     | 12.813                      |
| Not reported                        | 23 (37.1)                        | 7 (10.4)                      | (*** $P < 0.001$)           |

Values are presented as number (%).
Group 1 (partial compliance group): Guidelines converted RIGHT scores were under median level 49, Group 2 (well compliance group): Guidelines converted RIGHT scores were over median level 49.

* $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$.
questions. The evidence and recommendation sections are considered to easily meet the RIGHT Checklist requirements if the GRADE Evidence to Decision framework (GRADE EtD) is used (Supplementary Table 1).

This study’s strengths are that 1) it is possible that data acquisition was more complete because KAMS implemented it (KAMS is the most authoritative organization for CPG development in Korea), and 2) the authors who assessed compliances for the RIGHT Checklists were experienced CPG development experts and AGREE II appraisal experts.

This study has a limitation that there is a possibility that there are some CPGs in Korea that are not included because the literature search or medical society survey was not perfect.

In conclusion, this study evaluated RIGHT Checklist compliance of CPGs developed in Korea over the past five years and derived the support measures for implementing each checklist item. There was no specific link between the level of compliance of items and the supporting measures agreed upon by the ECC. However, based on this study’s results, the ECC expects that it can be used to develop strategic plans for enhancing the capabilities of developing CPGs in Korea.

ACKNOWLEDGMENTS

We would like to thank the ECC members of KAMS for providing many comments on the research and the Secretariat of the KAMS for providing administrative assistance in conducting the research.

SUPPLEMENTARY MATERIAL

Supplementary Table 1
The skills and the supporting measures needed to implement the RIGHT Checklist items

Click here to view

REFERENCES

1. Korean Medical Guideline Information Center (KOMGI). List of developed Korean Clinical Practice Guidelines. https://www.guideline.or.kr/guide/?sub_depth=3&c=1. Updated 2021. Accessed April 7, 2020.
2. Alonso-Coello P, Irfan A, Solà I, Gich I, Delgado-Noguera M, Rigau D, et al. The quality of clinical practice guidelines over the last two decades: a systematic review of guideline appraisal studies. *Qual Saf Health Care* 2010;19(6):e58. [PUBMED]
3. Lee YK, Shin ES, Shim JY, Min KJ, Kim JM, Lee SH, et al. Developing a scoring guide for the Appraisal of Guidelines for Research and Evaluation II instrument in Korea: a modified Delphi consensus process. *J Korean Med Sci* 2013;28(2):190-4. [PUBMED] [CROSSREF]
4. Oh MK, Jo H, Lee YK. Improving the reliability of clinical practice guideline appraisals: effects of the Korean AGREE II scoring guide. *J Korean Med Sci* 2014;29(6):771-5. [PUBMED] [CROSSREF]
5. Chang SG, Kim DI, Shin ES, Jang JE, Yeon JY, Lee YS. Methodological quality appraisal of 27 Korean guidelines using a scoring guide based on the AGREE II instrument and a web-based evaluation. *J Korean Med Sci* 2016;31(5):682-7.

6. Choi M, Kim N, Sheen S, Ji S, Lyu D, You J. Current status of clinical practice guideline development and dissemination in Korea for identifying collaborative research demands. *Evid Value* 2015;1(1):16-23.

7. EQUATOR. https://www.equator-network.org. Updated 2021. Accessed April 7, 2020.

8. Brouwers MC, Kerkvliet K, Spithoff K; AGREE Next Steps Consortium. The AGREE Reporting Checklist: a tool to improve reporting of clinical practice guidelines. *BMJ* 2016;352:i1152.

9. Chen Y, Yang K, Marušič A, Qaseem A, Meerpohl JJ, Flottorp S, et al. A reporting tool for practice guidelines in health care: the RIGHT statement. *Ann Intern Med* 2017;166(2):128-32.

10. Yao X, Ma J, Wang Q, Kanters D, Ali MU, Florez ID. A comparison of AGREE and RIGHT: which clinical practice guideline reporting checklist should be followed by guideline developers? *J Gen Intern Med* 2020;35(3):894-8.

11. Choi M, Kim SY, Lee YK; Executive Committee for Clinical Practice Guidelines, The Korean Academy of Medical Sciences. Current status of clinical practice guidelines in Korea. *J Korean Med Sci* 2021;36(6):e35.

12. Ji SM, Kim SY, Sheen SS, Heo DS, Kim NS. Consensus on definition and quality standard of clinical practice guideline using RAND method. *Health Policy Manag* 2010;20(2):146.